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ABSTRACT
This review highlights the potential benefits and challenges of the application of Hematopoietic Cell Therapy
(HCT) to the treatment of three rare genetic conditions affecting immunohematopoiesis early in life: IPEX
(Immune dysregulation, Polyendocrinopathy, X-linked), ALPS (Autoimmune Lymphoproliferative s.), and
Dyskeratosis Congenita (DC). Each of these conditions can result from several distinct genetic defects with
somewhat distinct clinical prognoses. Severe, life-threatening, autoimmune complications are seen with IPEX
and ALPS. In the DC disorders, marrow failure is a common abnormality. ALPS and DC are associated with
increased risk of hematopoietic malignancy. Early experience with HCT in these disorders predict that most
of the life-threatening complications of these conditions are reversible and/or preventable by HCT. In the
current era, it is advised that affected patients undergo definitive genetic diagnosis, and be considered for
reduced intensity HCT when young and relatively healthy.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
The ongoing discovery of genetic causes underlying
are disorders of immune and hematopoietic dysregula-
ion is shaping improvements in their therapy and de-
ning a role for HCT. In this review, we describe 3
roups of disorders involving genetic defects expressed
n cells of hematopoietic origin for which HCT holds
romise not only to reverse existing pathologies but also
o prevent new potential complications. Early attempts
o correct or stabilize these disorders with HCT were
hallenged by signiﬁcant pre-existing morbidities due to
hronic immunosuppressive therapy or end-organ dam-
ge. More recently, the application of reduced intensity
onditioning regimens coupled with improvements in
re-emptive viral detection have resulted in encouraging
esults with HCT in some patients.
MMUNODYSREGULATION POLYENDOCRINOPATHY
ND ENTEROPATHY, X-LINKED
linical Findings and Pathogenesis
Clinical onset of immunodysregulation polyendo-
rinopathy and enteropathy, X-linked (IPEX) symp- F
8oms occurs during the ﬁrst months of life and typi-
ally involves a constellation of insulin-dependant
iabetes, immune enteritis, and eczematous skin rash.
utoimmune thyroid disease and hemolytic anemia
ften follow [1,2]. Although patients with IPEX often
ave serious infections, these are usually attributed to
hronic enteritis, indwelling catheters, and the use of
ntense immunosuppression to control the autoim-
une symptoms, rather than intrinsic immunodeﬁ-
iency. A similar X-linked murine disorder, scurfy (sf),
haracterized by runting, lymphoid hyperplasia and
ymphocytic inﬁltration of many organs, scaly skin
ash, and early mortality, arose from spontaneous mu-
ation in an inbred mouse strain and was reported in
959 [3].
In addition to the discovery of the causal mutation
n the FOXP3 gene in sf mice in 2001 [4], deleterious
utations in the coding region of the human FOXP3
ene were identiﬁed in several families with IPEX
5,6]. The FOXP3 protein has several functional do-
ains characteristic of this protein family that are
nvolved with regulation of gene transcription. The
OXP3 gene is expressed almost exclusively in lym-
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Emerging Targets for HCT 59hoid tissues and the FOXP3 protein is found in
D25bright CD4 T cells in the circulation, the so-
alled natural Tregs, that arise within the thymus [7].
ultiple experimental models have shown that deple-
ion of natural Tregs enhances the incidence of auto-
mmune complications and favors prolonged and ex-
essive effector responses to infections, implicating
regs as a major suppressor T cell population.
A substantial proportion of patients (usually male)
ho have an IPEX phenotype lack mutations in the
OXP3 gene, although they may demonstrate de-
reased FOXP3 protein in the CD25 CD4T cells
possibly resulting from upstream mutations in rele-
ant regulatory elements [8]). Although there are still
imited experimental data with Tregs from IPEX pa-
ients, study of cell lines in vitro suggests that de-
reased expression of FOXP3 is associated with more
road-ranging immune dysregulation [9].
reatment of IPEX and Results with HCT
Current conventional treatment of IPEX consists
f long-term use of a calcineurin inhibitor (cyclo-
porin A or tacrolimus), often in combination with
teroids, to reduce lymphoproliferation and ectopic
ymphoid inﬁltration. Treatment endpoints are symp-
omatic relief of enteritis and other nondiabetic com-
lications. Because patients with IPEX produce mul-
iple autoantibodies, the use of Rituxan (anti-CD20
ntibody) is an attractive additional option, although
xperience is limited. More recently, use of sirolimus,
hich offers a mode of action different from that of
alcineurin inhibitors and may favor survival and func-
ion of partially crippled Tregs, is attracting interest
10]. Despite or because of the use of long-term im-
unosuppressive drugs, the lifespan of patients with
PEX and their quality of life remain markedly com-
romised.
In scurfy mice, partial BM transplant and trans-
er of T cell-enriched healthy splenocytes and
D4CD25 T cells, especially early in life, have
hown beneﬁt [11].
However, the ﬁrst 3 cases of HCT in human IPEX
ltimately failed due to opportunistic infections, al-
hough post-transplantation improvement in multiple
utoimmune pathologies were documented [2,12].
hose transplantations were undertaken before ge-
etic characterization of the disorder. More recently,
se of reduced intensity conditioning as the prepara-
ive regimen has resulted in persistent mixed chimer-
sm, with resolution of autoimmune symptoms (other
han diabetes) in all 6 cases (3 matched siblings, 3
nrelated donors) [8,9,13]. Four patients underwent
ransplantation at 2 yr of age. In these cases, the
resence of CD25CD4 cells expressing FOXP3
ith normal or increased intensity have been detected
fter transplantation, approaching normal numbers Aor age by 1 yr after transplantation [13]. In future
ases, demonstration of dysfunctional or absent Tregs
r other defects before transplantation, followed by
vidence of relevant immunologic reconstitution af-
erward, should be attempted.
UTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
linical Findings and Pathogenesis of Autoimmune
ymphoproliferative Syndrome
Autoimmune lymphoproliferative syndrome (ALPS)
s a prototypic disorder of abnormal lymphocyte ho-
eostasis. Defective programmed cell death of lym-
hocytes, also referred to as “apoptosis,” through the
as (CD95) pathway, occupies a central role in the
athogenesis of ALPS. This homeostatic pathway is
mportant for (a) maintenance of the limited contain-
ent capacity of the lymphoid compartment, (b) elim-
nation of autoreactive lymphocytes, and (3) preven-
ion of malignant transformation of lymphocytes [14].
n consequence, the main manifestations of ALPS are
ymphoproliferation, reﬂected in lymphadenopathy
nd hepatosplenomegaly, autoimmune disease, di-
ected mostly toward blood cells, and a highly in-
reased risk of lymphoma [15-17]. The key laboratory
bnormalities in ALPS are accumulation of T lym-
hocytes that express the alpha/beta (/) TCR, but
ack expression of CD4 or CD8 (/-double negative
cells [/-DNTCs]) in peripheral blood and lym-
hoid tissues, and defective Fas-mediated apoptosis in
itro [15,16]. The recognition that similar features are
resent in 2 murine models of autoimmune lympho-
roliferative disease led to the discovery of the molec-
lar basis of ALPS [18-20].
More than 200 patients with ALPS have been
dentiﬁed with inherited (germ-line) heterozygous
utations in the gene encoding Fas (TNFRSF6, clas-
iﬁed as ALPS type Ia). Many of these mutations are
inked to defective Fas-mediated apoptosis through
he mechanism of dominant negative interference
19,21]. Approximately 25% of patients with the clin-
cal ALPS phenotype do not have mutations in
NFRSF6. With the exception of several patients
dentiﬁed with mutations in the gene encoding Fas
igand (TNFSF6, ALPS type Ib) and the gene encod-
ng caspase 10 (CASP10, ALPS type II), these patients
resently lack a genetic diagnosis and are classiﬁed as
aving ALPS type III [15,16]. Most recently, a new
ubgroup of patients with ALPS has become apparent.
heir clinical phenotype is virtually identical to ALPS
ue to germline FAS mutations; however, they carry
omatic FAS mutations in their DNTCs and other
ymphocyte subsets, but not in cells of nonhematopoi-
tic origin [22-24]. Based on current estimates, this
roup, provisionally classiﬁed as having ALPS I-SM,
s becoming the second-largest group of patients with
LPS and a deﬁned genetic abnormality.
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A. H. Filipovich et al.60reatment of ALPS and Results with HCT
Treatment strategies for ALPS are directed at the
previously mentioned consequences of disturbed
ymphocyte homeostasis. With increasing under-
tanding of this disease, it has become apparent that
xpanded populations of DNTCs and other lympho-
yte subsets play an active role in the ongoing disease
athogenesis. Thus, the presence of these cells not
nly reﬂects defective clearance (the consequence of
erturbed apoptosis) but also may be associated with
econdary effects, contributing to the development of
utoimmunity and perhaps malignancies. The treat-
ent of lymphoproliferation, which previously relied
n steroid therapy, has been replaced by Fansidar and
ycophenolate mofetil, which appear to have a more
avorable therapeutic index than traditional immuno-
uppressive agents but, unfortunately, lack long-term
eneﬁts [15,25,26]. Rituxan has shown promise in the
reatment of complex or recalcitrant cytopenias [27],
nd rapamycin has reduced lymphoproliferation in a
urine model [28]. It is reassuring, thus far, that
ymphoma in patients with ALPS responds to conven-
ional chemotherapeutic treatments (consistent with
he notion that other apoptotic pathways are intact
nd can be effectively targeted). At this time, only
CT offers curative treatment for ALPS.
Only several reports regarding HCT in ALPS
ave been published. Together with other (unpub-
ished) cases (personal experience and personal com-
unications), it appears that about a dozen patients
ith a primary diagnosis of ALPS has undergone
ransplantation worldwide [29,30]. Although this does
ot provide much of a track record regarding the
fﬁcacy of HCT, several observations can be made.
he patients generally displayed severe clinical phe-
otypes, presenting at an early age and failing con-
entional immunosuppressive therapies. The geno-
ypes included homozygous dominant mutations,
ompound (double) heterozygous dominant muta-
ions, and heterozygous dominant mutations affecting
he death domain of FAS. Donors included haploiden-
ical relatives (parents), matched siblings, and matched
nrelated donors. Conditioning regimens containing
combinations of) myeloablative and immunosuppres-
ive drugs, commonly employed in lymphoprolifera-
ive disorders, were used without obvious complica-
ions. Most of these cases have led to successful
utcomes, with resolution of clinical and laboratory
eatures of ALPS (Figure 1). Results with these pa-
ients establish a proof of principle, that ALPS can be
ured by HCT, which provides a framework in which
o consider HCT in other (less severely affected) pa-
ients with ALPS. In addition to cases in which the
ndication for HCT was directly related to ALPS,
ther patients with ALPS have likely undergone trans-
lantation before ALPS was recognized as a disease wntity for (recurrent) lymphoma or with life-threaten-
ng autoimmune cytopenias.
The rationale for considering HCT in less severe
enotypes/phenotypes of ALPS includes several argu-
ents. First, there is no other curative treatment that
estores normal lymphocyte homeostasis. Second, the
ccumulated experience with ALPS makes it clear that
ew patients with ALPS are likely to lead a life without
he need for lifelong medical follow-up or (episodic)
reatment of disease manifestations. These manifesta-
ions and their treatments are associated with signiﬁ-
ant risks, morbidity, and mortality. Third, extensive
xperience in primary immunodeﬁciency disorders in-
icates that HCT is curative for such disorders.
Relations between disease phenotype and associ-
ted genotype have become better characterized in
LPS. Summarized, it appears that patients with mu-
ations affecting the intracellular death domain (DD)
f Fas, linking surface Fas ligand interaction to the
ntracellular death-inducing signaling pathway, have
ore profound defects in lymphocyte apoptosis [31].
oreover, lymphoma appears thus far to have been
onﬁned to patients with DD mutations. In addition,
isease penetrance is highest in cases with DD muta-
ions [16,21]. Thus, at present, patients with ALPS
nd DD mutations appear to be the most appropriate
andidates for HCT, followed by patients with muta-
ions affecting other intracellular domains. Patients
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igure 1. Immunophenotypic detection of double-negative T cells.
cells expressing the / TCR, but lacking expression of CD4 or
D8 (/-DNTCs) were determined in the patient before BMT
upper left; 54% of total T cells), approximately 1 yr after trans-
lantation (upper right; 1.2% of total T cells), and compared with
is twin brother and BM donor (lower left; 0.8%) and an age-
atched healthy control (lower right; 0.5% of total T cells).ith mutations in extracellular mutations appear to
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Emerging Targets for HCT 61ave less severe disease, keeping in mind that these are
eneral observations rather than “rules.” The indica-
ion for HCT in patients with ALPS who do not have
ermline mutations in FAS is unclear. There is expe-
ience to suggest that the clinical phenotype of ALPS
n the basis of germline defects in the gene encoding
aspase 10 is similar to ALPS with FAS-DD muta-
ions. Given the close interaction between caspase 10
nd the DD, this is perhaps not a surprise. In contrast,
n humans, caspase 8 is an alternative signal transduc-
ion molecule that can propagate the death signal in
he absence of caspase 10 [32]. Much needs to be
earned about the clinical phenotype and natural his-
ory of ALPS I-SM to understand the role, if any, of
CT. The absence of germline FAS mutations by
tself may not disqualify HCT as an appropriate ther-
py, as suggested by the beneﬁts of HCT for patients
ith other hematopoietic disorders due to somatic
utational events (eg, paroxysmal nocturnal hemo-
lobinuria and BM failure syndromes).
Because ALPS mainly affects homeostasis of lym-
hocytes, it may not be necessary to provide full BM
blation; reduced intensity conditioning may be ade-
uate to achieve normal lymphoid engraftment. If
ecent experience with use of reduced intensity con-
itioning HCT for ALPS is proved successful, HCT
ould and should be considered as a primary treatment
oal in ALPS, rather than as salvage therapy in pa-
ients with uncontrollable lymphoproliferation, in-
luding lymphoma and/or autoimmunity.
The question can be asked as to whether defective
as-mediated apoptosis has consequences for HCT. A
ide range of transplantation experiments has been
erformed in murine counterparts of ALPS: the lpr-
nd gld-based mouse models. In addition to conﬁrm-
ng the basic feasibility of HCT in this disorder, they
ave provided interesting insights into the role of the
as system in the context of the immunology of HCT
39,40]. From the standpoint of host-versus-graft and
raft-versus-host alloreactivity, an important ﬁnding
as been the role of donor T cells. If T cell-depleted
M was infused, lpr mice displayed an increased fre-
uency of BM rejection compared with non-lpr con-
rol mice. No signiﬁcant difference and no rejection
ere observed when unmanipulated (T cell replete)
M was used [40]. This observation could be related
o the fact that, although Fas ligand cannot interact
ith Fas in the (lpr) host, infusion of donor cells with
ntact Fas provides a target for Fas ligand expressed in
n upregulated fashion on residual host cells, thereby
nducing elimination of donor cells. Thus, immune-
ediated destruction of donor cells, in the context of
n increased state of activation or cytotoxic nature of
residual) host cells, could prove a barrier to donor
ngraftment. From the standpoint of graft-versus-host
lloreactivity, the experiments in lpr mice revealed
hat providing donor T cells in the BM graft was uufﬁcient to overcome this barrier to engraftment,
ut at the expense of increased GVHD morbidity
nd mortality (not observed in the non-lpr control
ice) [40].
Caution is urged when translating these murine
xperiments to patients with ALPS. However, because
any patients with ALPS have expanded subpopula-
ions of cytotoxic lymphocytes, notably the DNTCs
nd CD8 T cells that show upregulated expression
f Fas ligand and increased levels of soluble Fas
igand [16], a similar concern for resistance to en-
raftment should be considered, inviting careful
onsideration regarding conditioning, donor choice
eg, HLA compatibility), and source of stem cells
eg, unmanipulated BM).
YSKERATOSIS CONGENITA
linical Findings and Pathogenesis of Dyskeratosis
ongenita
Dyskeratosis congenita (DC) is an inherited mul-
isystem disorder of premature aging characterized by
arly BM failure. The 2 major forms of this disease,
-linked and autosomal dominant (AD), are associ-
ted with mutations in speciﬁc genes that control
elomerase activity and are components of the telom-
rase complex. In the X-linked form, DKC1 gene
utations have been found that affect dyskerin expres-
ion, a small nucleolar ribonucleoprotein involved in
ibosomal RNA processing [41]. In AD DC, several
ifferent mutations have been identiﬁed in the RNA
omponent of telomerase, referred to as “hTERC”
42]. An autosomal recessive form of this disorder also
xists, although the molecular defect has yet to be
dentiﬁed conclusively. These mutations led to de-
reased telomerase activity and subsequent telomere
hortening in somatic cells. Although telomere short-
ning is a normal consequence of aging, accelerated
elomere shortening promotes cellular senescence and
ysfunction [43]. Not surprisingly, the effects of telo-
ere shortening are most profound in cells with a
igh proliferative capacity, such as those derived from
he BM and skin, “sites” of clinical disease in DC [44].
n vitro studies have also shown proliferative defects in
C keratinocytes, lymphocytes, and hematopoietic
tem cells (Goldman, unpublished observations). In
ddition, telomere shortening in DC lymphocytes
ay correlate with disease progression, as noted by
he ﬁnding of “disease anticipation” in AD DC [45].
linical manifestations of DC most often include ab-
ormal skin pigmentation, nail dystrophy, and leuko-
lakia. Other somatic abnormalities include pulmo-
ary ﬁbrosis, hair loss, and liver disease, and affected
atients have an increased risk of developing malig-
ancies [46]. Nonetheless, pancytopenia and BM fail-
re are the primary causes of morbidity and mortality
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A. H. Filipovich et al.62n DC. Although information regarding outcome and
ife expectancy in AD DC is limited, registry data
uggest that 50% of patients with X-linked DC will
evelop severe and life-threatening aplasia by 20 yr of
ge, increasing to 95% by 40 yr of age [46].
reatment of DC and Results of HCT
Different treatment strategies have been em-
loyed for BM failure associated with DC. Immuno-
uppressive drugs, growth factors, and anabolic ste-
oids have limited long-term beneﬁt. The deﬁnitive
reatment for aplastic anemia in DC remains alloge-
eic HCT, although results to date have been far
nferior to those seen in aplastic anemia and other
ongenital marrow failure disorders. To date, there
ave been approximately 40 published cases of pa-
ients with DC undergoing BMT and likely others
hat have not been reported. Different early and late
ntoward side effects have been observed after trans-
lantation, notably interstitial pneumonitis, lung ﬁ-
rosis, microangiopathies, and other vascular compli-
ations [47-49]. Underlying occult organ dysfunction
nd pulmonary disease may in part be responsible for
he increased morbidity observed after transplanta-
ion, although recent data suggest that DC cells may
lso have an increased sensitivity to cytotoxic agents
50]. As such, strategies to minimize post-transplanta-
ion complications have been employed, including use
f reduced intensity conditioning regimens, avoidance
f radiation and busulfan, and selection of umbilical
ord blood as a source of allogeneic hematopoietic
tem cells [47,51]. Even with these modiﬁcations,
ransplantation success rates only approach 50%.
ther treatment strategies for BM failure in DC,
ncluding a gene transfer approach, need to be ex-
lored.
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